TrialArthritis & rheumatology (Hoboken, N.J.)2026

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study.

Alexis Ogdie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.